Double-blind, vehicle-controlled, multicenter comparison of two 0.025% tretinoin creams in patients with acne vulgaris

Lucky, Anne W.; Cullen, Stanley I.; Funicella, Toni; Jarratt, Michael; Jones, Terry C.; Reddick, Max E.

doi:10.1016/s0190-9622(98)70142-2

Cited by 42 publications

(16 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Topical tretinoin was assessed in 14 12,16,17,[20][21][22][23][24][25][26][27][28]30,31 studies including 7 RCT, 4 case reports, and 3 single-arm trials. One study presented results for two RCT separately and was extracted as two studies.…”

Section: Study Characteristicsmentioning

confidence: 99%

“…One study presented results for two RCT separately and was extracted as two studies. 23 Among the studies investigating topical tretinoin, 5 studies 12,21,25,26,28 assessed the use of tretinoin in the treatment of acne; 5 studies 20,23,30,31 used tretinoin for the treatment of photodamaged skin; 3 studies 16,17,27 assessed its efficacy in the treatment of cervical intraepithelial neoplasia; and one study, a case report, reported the use of topical tretinoin for the treatment of a ''brown macule.'' 24 Other topical retinoids investigated included adapalene, alitretinoin, isotretinoin, and tazarotene.…”

Section: Study Characteristicsmentioning

confidence: 99%

“…There were 5 placebo-controlled trials assessing topical tretinoin. 20,21,23,30 In these trials, 142/500 (28.4%) patients in the topical tretinoin groups reported at least one noncutaneous AE. Among patients in the placebo groups, 108/428 (25.2%) reported at least one noncutaneous AE.…”

Section: Safetymentioning

confidence: 99%

“…In addition, two Among patients enrolled in the placebo arms of the tretinoin trials, the most common noncutaneous AE were infections (55 patients) and respiratory events (9 patients). One study 21 reported the occurrence of ''noncutaneous adverse events'' in 25 patients.…”

Section: Safetymentioning

confidence: 99%

See 3 more Smart Citations

Use of topical tretinoin and the development of noncutaneous adverse events: Evidence from a systematic review of the literature

Shapiro

Heremans

Mays

et al. 2011

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

Section: Study Characteristicsmentioning

confidence: 99%

Section: Study Characteristicsmentioning

confidence: 99%

Section: Safetymentioning

confidence: 99%

Section: Safetymentioning

confidence: 99%

See 2 more Smart Citations

Use of topical tretinoin and the development of noncutaneous adverse events: Evidence from a systematic review of the literature

Shapiro

Heremans

Mays

et al. 2011

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

“…As seen in Figure 1, topical retinoids (e.g., tretinoin) or topical retinoid analogs (e.g., adapalene, tazarotene) constitute foundation therapy for most of the stages of acne vulgaris, including the maintenance phase. All formulations of topical retinoids and retinoid analogs have demonstrated efficacy against comedonal and inflammatory lesions 9–14 . During the maintenance phase, other factors of a drug regimen, such as simplicity and tolerability, become especially important.…”

mentioning

confidence: 99%

How Do You Foster Medication Adherence for Better Acne Vulgaris Management?

Koo

2003

Skinmed

View full text Add to dashboard Cite

Suboptimal medication adherence is one of the major reasons for treatment failure among patients with acne vulgaris. Motivating patients to adhere to treatment, especially during the maintenance phase, remains a challenge. Although the literature on medication adherence in the acne vulgaris patient population is sparse, the available literature on patients with dermatologic and nondermatologic disorders suggests that a multifactorial approach, combining nonpharmacologic interventions and effective, well tolerated, and simplified drug regimens, appears to be associated with the greatest success. Furthermore, it is important to evaluate the patient for underlying affective disorders (e.g., depression) that can undermine adherence. The dermatologist can play a major role in enhancing patient adherence by prescribing adherence-enhancing therapeutic regimens and by forming a therapeutic alliance with patients.

show abstract

New Treatments and Therapeutic Strategies for Acne

Thiboutot

2000

Archives of Family Medicine

View full text Add to dashboard Cite

Successful management of acne requires careful patient evaluation followed by consideration of several patient and medication factors when selecting a particular therapeutic regimen. Within the last few years, several new agents for the treatment of acne have become available that afford greater flexibility in the treatment of this prevalent dermatologic disorder. These include adapalene, tazarotene, 2 new topical tretinoin formulations, azelaic acid, a new sodium sulfacetamide formulation, and an oral contraceptive recently approved by the Food and Drug Administration for the treatment of acne. After a brief overview of the pathophysiology of acne and existing therapies, this review evaluates the new antiacne agents and how they can be integrated into a successful treatment strategy that takes into account acne severity and predominant lesion type as well as age, skin type, lifestyle, motivation, and the presence of coexisting conditions.

show abstract

Double-blind, vehicle-controlled, multicenter comparison of two 0.025% tretinoin creams in patients with acne vulgaris

Cited by 42 publications

References 7 publications

Use of topical tretinoin and the development of noncutaneous adverse events: Evidence from a systematic review of the literature

Use of topical tretinoin and the development of noncutaneous adverse events: Evidence from a systematic review of the literature

How Do You Foster Medication Adherence for Better Acne Vulgaris Management?

New Treatments and Therapeutic Strategies for Acne

Contact Info

Product

Resources

About